A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma

Lymphoma Clinical Trial

Official title:

A Phase I/II Trial of Combination Bortezomib (VELCADE) and Gemcitabine Therapy for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00290706
• Other study ID #: NU 04H4
• Secondary ID: NU 04H4VEL-03-08
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: April 7, 2006
• Est. completion date: September 5, 2012

Study information

• Verified date: May 2019
• Source: Northwestern University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving gemcitabine together with bortezomib may kill more cancer cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of bortezomib when given together with gemcitabine and to see how well they work in treating patients with relapsed or refractory B-cell or T-cell non-Hodgkin's lymphoma.

Description:

OBJECTIVES:

Primary

• Determine the response rate (complete and partial remission) in patients with relapsed or refractory aggressive B- or T-cell non-Hodgkin's lymphoma treated with gemcitabine hydrochloride and bortezomib.

• Determine the maximum tolerated dose of bortezomib when administered with gemcitabine hydrochloride in these patients.

Secondary

• Determine the time to treatment failure, duration of response, and overall survival of patients treated with this regimen.

• Determine the safety and tolerability of this regimen in these patients.

OUTLINE: This is a phase I, dose-escalation study of bortezomib followed by a phase II, open-label study.

• Phase I: Patients receive gemcitabine hydrochloride IV over 30 minutes and bortezomib IV over 3-5 seconds on days 1 and 8. Treatment repeats every 21 days for up to 9 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of bortezomib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 3 of 6 patients experience dose-limiting toxicity (DLT) OR the dose that at which 2 of 6 patients experience DLT.

• Phase II: Patients receive gemcitabine hydrochloride and bortezomib as in phase I at the MTD.

After completion of study therapy, patients are followed periodically for 3 years.

PROJECTED ACCRUAL: A total of 37 patients will be accrued for this study.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 32
• Est. completion date: September 5, 2012
• Est. primary completion date: February 11, 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

DISEASE CHARACTERISTICS:

• Diagnosis of B- or T-cell non-Hodgkin's lymphoma (NHL)

• Intermediate histology B-cell NHL, including any of the following:

• Diffuse large B-cell lymphoma

• Transformed large cell lymphoma

• Any T-cell NHL histology

• Cutaneous T-cell lymphoma (CTCL) or mycosis fungoides (MF) allowed

• Relapsed or refractory disease, defined as disease progressed after prior complete remission (CR), partial remission (PR), or stable disease (SD) to last therapy OR failure to achieve CR, PR, or SD after completion of last therapy

• Must have received 1-3 prior therapeutic regimens

• Cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (CHOP) AND cyclophosphamide, vincristine, and prednisone (CVP) OR CHOP with rituximab (CHOP-R) AND CVP with rituximab (CVP-R) is considered 1 regimen

• Monoclonal antibody (e.g., rituximab) given as maintenance therapy is considered 1 regimen

• Salvage chemotherapy followed by an autologous stem cell transplant is considered 1 regimen

• No more than 7 prior therapeutic regimens for patients with CTCL or MF

• No mantle cell lymphoma

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2

• Life expectancy > 3 months

• Absolute neutrophil count = 1,500/mm^3

• Platelet count = 100,000/mm^3

• At least 50,000/mm^3 if documented bone marrow involvement

• Hemoglobin = 8.0 g/dL

• AST and ALT = 3 times upper limit of normal (ULN)

• Alkaline phosphatase = 3 times ULN

• Bilirubin = 2 times ULN

• Creatinine = 2.0 mg/dL

• No known history of HIV infection

• No other active infection

• No uncontrolled hypertension

• No peripheral neuropathy = grade 2 within the past 2 weeks

• No myocardial infarction within the past 6 months

• No New York Heart Association class III or IV heart failure

• No uncontrolled angina

• No severe uncontrolled ventricular arrhythmias

• No acute ischemia or active conduction system abnormalities by ECG

• No hypersensitivity to bortezomib, boron, or mannitol

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective barrier-method contraception

• No serious medical or psychiatric illness that would preclude study participation

PRIOR CONCURRENT THERAPY:

• Prior autologous and/or allogeneic stem cell transplantation allowed

• More than 3 weeks since prior chemotherapy, radiotherapy, or immunotherapy

• More than 3 weeks since prior systemic biologic anticancer therapy

• More than 3 weeks since prior systemic corticosteroids (e.g., oral prednisone > 10 mg per day)

• More than 2 weeks since prior investigational drug

• No prior bortezomib or gemcitabine hydrochloride

• No other concurrent systemic cytotoxic chemotherapy or investigational agents

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, Non-Hodgkin
• Lymphoma, T-Cell

Intervention

Drug:
• bortezomib
Bortezomib 1.6mg/m2 on days 1 and 15 of each cycle, given over 3-5 seconds on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
• gemcitabine hydrochloride
Gemcitabine dose of 800 mg/m2 over 30 minutes on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.

Locations

Country	Name	City	State
United States	Northwestern University	Chicago	Illinois
United States	University of Chicago Cancer Research Center	Chicago	Illinois
United States	Veterans Affairs Medical Center - Lakeside Chicago	Chicago	Illinois

Sponsors (3)

Lead Sponsor	Collaborator
Northwestern University	Eli Lilly and Company, Millennium Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response Rate in Patients With Relapsed or Refractory B- and T-cell NHL With Gemcitabine and Bortezomib Combination Treatment.	Response rate in patients with relapsed or refractory B- and T-cell NHL with Gemcitabine and Bortezomib combination treatment will be defined as the number of patients with Complete Remission [CR] and Partial Remission [PR]. CT scans at screening and after completing cycle 3, cycle 6 and 30 days after Cycle 8 assessed by the Response Criteria for Non-hodgkins Lymphoma will be used to determine response where: CR=Complete disappearance of all detectable clinical and radiographic evidence of disease PR=> 50% decrease in SPD of the six largest dominant nodes or nodal masses	At screening and after completing cycle 3, cycle 6 and 30 days after Cycle 8
Secondary	Time to Treatment Failure and Duration of Response	Time to treatment failure and duration of response will be measured by CT Scan at screening and after completing cycle 3, cycle 6 and 30 days after cycle 8, then every 6 months for 3 years	At screening and after completing cycle 3, cycle 6 and 30 days after cycle 8, then every 6 months for 3 years
Secondary	Overall Survival	Overall survival will be evaluated every 6 months while on treatment and then every 6 months while off of treatment for up to 3 years	Every 6 months while on treatment and then every 6 months while off of treatment for up to 3 years
Secondary	Evaluate Safety and Tolerability of Bortezomib and Gemcitabine Therapy	Safety and tolerability of the study drugs will be assessed on Day 1 and on either Day 8 or Day 15 of each treatment cycle (1 Cycle - 28 days) while on active treatment; and 30 days post last treatment. Adverse Events that are experienced by patients, determined to be either grade 3 or grade 4 and at least possibly related to at least one of the study drugs as assessed according to the National Cancer Institute's Common Toxicity Criteria for adverse events version 3.0 (CTCAE v3.0) will be collected. In general adverse events (AEs) will be graded according to the following: Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE	During treatment through a maximum of 8 Cycles (1 Cycle = 28 Days) and 30 days post last treatment